Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study
1. BMEA's stock price fell 33.9% to $1.76 after a public offering. 2. The offering includes 11.2 million shares, priced at $2.05 each. 3. Concerns over stock dilution negatively influenced investor sentiment. 4. Icovamenib showed promising results in a recent clinical study. 5. Future trials for new therapies are expected by late 2025 and 2026.